Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Reaches $28.07 52-Week Low; Novo A Has Upped Acceleron Pharma (XLRN) Position

May 30, 2017 - By Vivian Currie

The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) hit a new 52-week low and has $25.54 target or 9.00% below today’s $28.07 share price. The 9 months bearish chart indicates high risk for the $28.16B company. The 1-year low was reported on May, 30 by Barchart.com. If the $25.54 price target is reached, the company will be worth $2.53 billion less. About 3.70M shares traded. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since May 30, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.

Novo A increased Acceleron Pharma Inc (XLRN) stake by 37.21% reported in 2016Q4 SEC filing. Novo A acquired 336,340 shares as Acceleron Pharma Inc (XLRN)’s stock declined 4.63%. The Novo A holds 1.24M shares with $31.65 million value, up from 903,833 last quarter. Acceleron Pharma Inc now has $948.56M valuation. The stock rose 1.90% or $0.48 reaching $25.73 per share. About 72,076 shares traded. Acceleron Pharma Inc (NASDAQ:XLRN) has declined 22.43% since May 30, 2016 and is downtrending. It has underperformed by 39.13% the S&P500.

Among 24 analysts covering Teva Pharma (NYSE:TEVA), 12 have Buy rating, 1 Sell and 11 Hold. Therefore 50% are positive. Teva Pharma had 57 analyst reports since July 21, 2015 according to SRatingsIntel. Wells Fargo downgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Monday, January 9 to “Market Perform” rating. The firm has “Neutral” rating by Mizuho given on Monday, October 24. The stock has “Buy” rating by Goldman Sachs on Monday, November 23. The stock has “Neutral” rating by JP Morgan on Friday, January 20. The stock has “Overweight” rating by Morgan Stanley on Tuesday, May 3. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Buy” rating by Maxim Group on Wednesday, November 16. The firm has “Positive” rating by OTR Global given on Thursday, September 29. The rating was maintained by Maxim Group on Wednesday, January 4 with “Buy”. The firm has “Outperform” rating given on Tuesday, July 21 by Leerink Swann. The rating was maintained by Maxim Group on Monday, February 13 with “Hold”.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The company has market cap of $28.16 billion. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. It has a 265.69 P/E ratio. The Firm operates through two divisions: Generic medicines and Specialty medicines.

Since December 7, 2016, it had 0 insider buys, and 6 insider sales for $1.35 million activity. $46,513 worth of Acceleron Pharma Inc (NASDAQ:XLRN) shares were sold by Quisel John D. On Wednesday, January 4 the insider Sherman Matthew L sold $54,916. $46,667 worth of Acceleron Pharma Inc (NASDAQ:XLRN) shares were sold by MCLAUGHLIN KEVIN F. $54,916 worth of Acceleron Pharma Inc (NASDAQ:XLRN) was sold by Kumar Ravindra on Wednesday, January 4. $68,611 worth of Acceleron Pharma Inc (NASDAQ:XLRN) shares were sold by Ertel Steven D. $1.08M worth of Acceleron Pharma Inc (NASDAQ:XLRN) was sold by MCGUIRE TERRANCE on Wednesday, December 7.

Among 10 analysts covering Acceleron Pharma (NASDAQ:XLRN), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Acceleron Pharma had 15 analyst reports since August 13, 2015 according to SRatingsIntel. Oppenheimer initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Tuesday, December 13 with “Outperform” rating. The firm earned “Neutral” rating on Thursday, December 17 by Janney Capital. Barclays Capital initiated Acceleron Pharma Inc (NASDAQ:XLRN) rating on Wednesday, April 27. Barclays Capital has “Overweight” rating and $40 target. Citigroup initiated Acceleron Pharma Inc (NASDAQ:XLRN) rating on Thursday, September 29. Citigroup has “Neutral” rating and $40 target. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) earned “Outperform” rating by Oppenheimer on Friday, November 20. The firm has “Outperform” rating given on Monday, February 1 by Oppenheimer. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. Barclays Capital maintained Acceleron Pharma Inc (NASDAQ:XLRN) rating on Monday, June 13. Barclays Capital has “Overweight” rating and $42 target. On Thursday, March 2 the stock rating was upgraded by Citigroup to “Buy”. The firm earned “Outperform” rating on Monday, January 18 by FBR Capital.

Investors sentiment increased to 1.35 in 2016 Q4. Its up 0.35, from 1 in 2016Q3. It is positive, as 21 investors sold XLRN shares while 34 reduced holdings. 25 funds opened positions while 49 raised stakes. 31.42 million shares or 3.11% more from 30.48 million shares in 2016Q3 were reported. Laurion Limited Partnership stated it has 202,738 shares or 0.05% of all its holdings. State Board Of Administration Of Florida Retirement Sys holds 0% or 18,198 shares. 135,621 were reported by National Bank & Trust Of New York Mellon. Novo A S has invested 3.01% in Acceleron Pharma Inc (NASDAQ:XLRN). Amer Century Cos Inc holds 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN) for 31,768 shares. Brown Brothers Harriman & stated it has 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Da Davidson Comm, Montana-based fund reported 2,292 shares. Sei Invests holds 300 shares. Guggenheim Ltd has 66,406 shares. Foresite Capital Management Ii reported 19,910 shares. Royal National Bank Of Canada reported 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Glenmede Communications Na invested in 0% or 13,186 shares. Blackrock reported 78,860 shares or 0% of all its holdings. Aqr Mngmt Limited holds 0% in Acceleron Pharma Inc (NASDAQ:XLRN) or 18,568 shares. Vanguard Grp Incorporated holds 1.75M shares or 0% of its portfolio.